22 October 2020

U.S. FDA Grants Fast Track Designation to Amarex Client PRG S&T Inc.

Amarex Taiwan, LLC, an NSF International company announced that the U.S. FDA granted Fast Track designation to Amarex’s client PRG S&T Inc. for PRG’s drug Progerinin, being tested as a treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS). The Phase I study will be conducted in healthy subjects.

13 October 2020

Free webinar : Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design| October 27, 2020 11:00 AM EDT

Amarex Taiwan, LLC, an NSF International company’s Senior Vice President of Clinical Operations, Dr. Kush Dhody, will conduct a free webinar on Tuesday, October 27, 2020 at 11:00 a.m. EDT entitled Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design.

​

Register for this free webinar.

08 October 2020

Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis

Amarex client, Amytrx Therapeutics (“Amytrx”), recently initiated clinical testing of their anti-inflammatory therapeutic product AMTX-100 for dermatological diseases and conditions with the enrollment of patients in a first-in-man Phase 1/2b study for treatment of mild to moderate atopic dermatitis.

22 September 2020

Amarex to Support AIM ImmunoTech in Regulatory Filings for Exciting Pancreatic Cancer Treatment under Development

Amarex Taiwan, LLC (Amarex) client AIM ImmunoTech Inc. (NYSE American: AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus Medical Center in the Netherlands.